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Abstract 
Background: Calcific aortic stenosis (CAS) is the most common heart valve disease in the elderly, representing an 
important economic and social burden in developed countries. Currently, there is no way to predict either the onset 
or progression of CAS, emphasizing the need to identify useful biomarkers for this condition.
Methods: We performed a multi‑proteomic analysis on different kinds of samples from CAS patients and healthy 
donors: tissue, secretome and plasma. The results were validated in an independent cohort of subjects by immuno‑
histochemistry, western blotting and selected reaction monitoring.
Results: Alpha 1 antichymotrypsin (AACT) abundance was altered in the CAS samples, as confirmed in the validation 
phase. The significant changes observed in the amounts of this protein strongly suggest that it could be involved in 
the molecular mechanisms underlying CAS. In addition, our results suggest there is enhanced release of AACT into 
the extracellular fluids when the disease commences.
Conclusions: The significant increase of AACT in CAS patients suggests it fulfils an important role in the physiopa‑
thology of this disease. These results permit us to propose that AACT may serve as a potential marker for the diagnosis 
of CAS, with considerable clinical value.
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Background
Calcific aortic valve stenosis (CAS) is the most preva-
lent heart valve disease in Europe and North America, 
and it is currently responsible for most of the aortic valve 
replacement procedures that are performed [1, 2]. CAS 
is age-related and given the aging population in occiden-
tal countries, its prevalence is expected to increase in 
the forthcoming decades [3]. The natural history of CAS 
involves a long clinically silent phase of valve calcification 
and hardening (valve sclerosis) that generally requires at 
least a decade before heralding the clinical disease. CAS 
is characterized by an initial stage that has a pathogen-
esis similar to atherosclerosis, and an active pathology 
that is characterized by lipid accumulation, inflammation 
and calcification [4]. Hemodynamically, CAS involves 
obstructed blood flow at the level of the aortic valve, with 
a pressure gradient between the left ventricular (LV) and 
the ascending aorta. The increased LV pressure enhances 
myocardial wall stress, which is at first compensated by LV 
hypertrophy, but that is followed by LV dilation and sys-
tolic dysfunction during the later stages of the disease [5].
At present, aortic valve replacement is the only effective 
treatment for severe symptomatic CAS, whereas in most 
asymptomatic patients the risk of surgery outweighs that of 
disease monitoring. Therefore, asymptomatic patients with 
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CAS are managed through regular clinical and echocar-
diography check-ups, as well as basic education to modify 
their lifestyle and to provide awareness of cardiac risk fac-
tors [6]. Nevertheless, it is necessary to develop markers that 
can guide clinicians to classify patients at high or low risk 
of disease progression and subsequently tailor their follow-
up frequency, thereby optimizing healthcare resources and 
reducing costs [7]. The possibility of predicting the develop-
ment of CAS in patients would be tremendously useful.
Here, we have adopted an omics strategy to perform an 
unbiased, non-targeted study of CAS. Our data show the 
importance of the alpha 1 antichymotrypsin (AACT) pro-
tein in CAS, for the first time describing its potential as a 
future diagnostic marker of this disease. This protein is asso-
ciated with the acute-phase of the disease, placing the focus 
on inflammatory processes in relation to the mechanisms 
underlying CAS. Moreover, the potential predictive value of 
AACT was validated through a selected reaction monitor-
ing (SRM) analysis in plasma samples, which could facilitate 
its future implementation in clinical practice (Fig. 1).
Methods
Patient and control samples
Stenotic heart valves (n = 20) were obtained from severe 
symptomatic CAS patients (55% male, 45% female), with 
an average age of 74 (SD = 4.0) years, who underwent aor-
tic valve replacement. All patients had hypertension, 50% 
suffered hyperlipidemia and 60% diabetes mellitus. Patients 
with a medical history of significant aortic regurgitation, 
rheumatic fever or morphological valve alterations consist-
ent with rheumatic heart disease, we’re excluded from the 
study (Table  1). The valves were classified according to a 
macroscopic inspection performed blind by cardiovascu-
lar surgeons. Normal valves (n = 20) from the autopsies of 
subjects who had died due to non-cardiovascular diseases 
were obtained within 4  h of death and used as controls 
(Table 2). In all the cases, the structure of both the stenotic 
and non-stenotic valves was 3-cuspid. 
For the SRM validation analysis, peripheral blood sam-
ples were collected from CAS patients (n = 8) and control 
subjects (n =  8) selected to avoid significant differences 
between the groups in terms of age (p  =  0.6), gender 
(p = 0.32), obesity (p = 0.5), hypertension (p = 0.5), dys-
lipidemia (p =  0.5) and diabetes (p =  0.7: Table 3). This 
study was carried out in accordance with the recommen-
dations of the Helsinki Declaration and it was approved by 
the ethics committee at the Hospital “Virgen de la Salud” 
(Toledo, Spain). Signed informed consent was obtained 
from all the subjects or their relatives (in case of necrop-
sies) prior to their inclusion in the study.
Tissue sample preparation
Aortic valves were preserved and transported in PBS, and 














Fig. 1 Schematic representation of the workflow. Samples were collected from valve replacement surgeries (AS) and autopsies (controls). During 
the discovery phase the whole tissue and secretome were analyzed and AACT was identified. Finally, AACT was validated as a potential biomarker in 
WBs, and by IHC and SRM
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valves were washed immediately in PBS to reduce blood 
contaminants. For 2D-DIGE and western blotting, one 
aortic valve leaflet was ground into a powder in liquid 
 N2 in a mortar. Protein extracts were then prepared from 
the valve as described previously [8, 9] and the total pro-
tein concentration was measured by the Bradford-Lowry 
method (Bio-Rad protein assay) [10].
For secretome analysis, the second valve leaaflet was 
cultured as described elsewhere [11, 12] using medium 
supplemented with antibiotics and amphotericin B 
 (Fungizone®) to avoid contamination. Samples were 
transferred to a Petri dish (Cell  Star®), cut into pieces 
and incubated at 37  °C in lysine-arginine free 1640 
RPMI medium (Cell Culture Technologies Invitrus) 
supplemented with 5  mg/ml fungizone, 250  mg/ml 
amikacin, 2  mg/ml  l-lysine 2HCl (U-13C6, 97–99%) 
and 10 mg/ml l-Arginine HCl (U-13C6, 97–98%: Cam-
bridge Isotope Laboratories Inc., Andover, MA) in a 
humidified atmosphere of 5%  CO2. The valves were cul-
tured for 96 h and the medium collected was stored at 
−80  °C until analysis. Finally, the valves were fixed in 
formalin at 4 °C, decalcified in Shandon-TBD1 (Thermo 
Scientific) and embedded in OCT for subsequent 
immunohistochemistry.
Plasma sample preparation
Blood samples were collected in tubes containing EDTA 
and centrifuged at 1125×g for 15  min. The resulting 
supernatant was frozen immediately at −80  °C until 
analysis.
2D‑DIGE separation, image acquisition and analysis
Tissue proteins were labeled according to the 
manufacturer´s instructions (GE Healthcare), and as 
described by Gil-Dones and Martin-Rojas [8, 9]. In all 
experiments an internal standard was added contain-
ing equal amounts of each protein extract. The internal 
standard and protein extracts from one stenotic and 
one control valve were combined and run on a single gel 
(150 μg of total protein). The proteins were separated by 
isoelectric focusing in the first dimension and the strips 
were then equilibrated via two consecutive incubations 
in SDS-equilibration buffer (1.5 M Tris∙HCl [pH 8.8], 6 M 
Table 1 Clinical characteristics of AS patients
F female, M male, AHT arterial hypertension
Patient  
number
Age/gender AHT Diabetes Dyslipidemia
1 74/F Yes No Yes
2 73/M Yes Yes No
3 68/M Yes No Yes
4 81/M Yes No Yes
5 69/M Yes Yes Yes
6 79/F Yes Yes No
7 73/F Yes Yes Yes
8 77/M Yes No No
9 79/F Yes Yes No
10 75/M Yes No Yes
11 74/M Yes Yes Yes
12 74/F Yes Yes No
13 79/F Yes Yes No
14 79/F Yes Yes No
15 72/F Yes No No
16 63/M Yes No Yes
17 72//M Yes No Yes
18 75/F Yes Yes Yes
19 78/M Yes Yes No
20 74/M Yes Yes No
Mean 74 ± 0/45% 
F–55% M
100.00% 60.00% 50.00%
Table 2 Clinical characteristics of control subjects













2 51/F Septic shock Yes No No
3 47/H Sepsis No No No
4 47/F Bacterial pneu‑
monia
No No No
5 47/F Carcinogenesis No No No
6 34/M Acute Pancrea‑
titis
Yes No No




9 42/F Lymphoma No No No
10 67/M Renal insuffi‑
ciency
No No No
11 74/M COPD No No No
12 87/F Carcinoma No No No




14 55/M Pneumonia No No No
15 87/F Cholelithiasis No No No
16 76/M Carcinoma No No No
17 80/F Atrial fibrillation Yes Yes No
18 49/F Respiratory 
insufficiency
No No No
19 74/M Septic shock Yes No Yes
20 77/F COPD Yes No No
Mean 69 ± 7.07/40% 
M–60% F
25.00% 5% 5%
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Urea, 87% Glycerol and 2% SDS) plus dithiothreitol and 
iodoacetamide, respectively. Subsequently, the proteins 
were separated on 12% Acrylamide/Bisacrylamide gels 
using an EttanDalt Six device (GE Healthcare), which 
were then scanned using a Typhoon 9400 fluorescence 
gel scanner (GE Healthcare). Relative protein quantifica-
tion of Aortic Stenosic (AS) and healthy valves was per-
formed with DeCyder software v6.5 (GE Healthcare) and 
with the multivariate statistical module EDA (Extended 
data analysis). Only proteins with >1.5-fold differences 
in abundance were considered significant. A statistical 
analysis was then carried out to determine the changes in 
protein expression, with p values below 0.05 accepted as 
significant when the Student’s t test was applied.
Protein identification by MALDI‑TOF/TOF
2D-DIGE gels were silver stained to visualize the pro-
tein spots, and all differentially expressed protein spots 
were then manually excised and identified at the Hospi-
tal Nacional de Paraplejicos’ Proteomics Unit. The pro-
teins were automatically digested in an “Ettan Digester” 
(GE Healthcare) according to Shevchenko et  al. [13], 
with minor modifications. An aliquot of each digestion 
was mixed with an aliquot of the matrix solution and 
this mixture was pipetted directly onto the stainless steel 
sample plate of the mass spectrometer.
The MALDI-MS/MS data were obtained in an auto-
mated analysis loop using a 4800 Plus MALDI TOF/
TOF Analyzer (Applied Biosystems). The spectra were 
acquired and the mass data were analysed automatically 
with the 4000 Series Explorer Software version 3.5.3 
(Applied Biosystems). MALDI-MS and MS/MS data were 
combined through the GPS Explorer Software (Version 
3.6) to search a non-redundant protein database (Swis-
sprot 56.5) using the Mascot software (version 2.2: Matrix 
Science) [14].
LC–MS/MS identification
Labeled peptide samples from secretome experiments 
were analyzed by LC–MS/MS using a C-18 reversed 
phase nano-column (75 µm I.D. × 50 cm, 2 µm particle 
size, nanoEASY 100 C18: Thermo Fisher Scientific) and a 
continuous acetonitrile gradient of: 0–30% B in 420 min, 
30–43% A in 5  min, and 43–90% B in 1  min (where: 
A = 0.5% formic acid; B = 90% acetonitrile, 0.5% formic 
acid). A flow rate of 200 nL/min was used to elute the 
peptides from the reverse phase nano-column to an emit-
ter nanospray needle for real time ionization and peptide 
fragmentation in a QExactive Hybrid Quadrupole-Orbit-
rap mass spectrometer (Thermo Fisher Scientific).
Western blotting
Protein extracts from CAS and control valves were 
resolved by 12% SDS-PAGE using a Bio-Rad Minipro-
tean II electrophoresis unit run for 1  h at a constant 
current of 25  mA/gel. After SDS-PAGE, the proteins 
were transferred to a nitrocellulose membrane under a 
constant voltage of 15 V for 20 min. Ponceau S staining 
was performed to guarantee that equal amounts of aor-
tic valve proteins were loaded onto the IPG strips (2-D 
western blotting) or onto polyacrylamide gels (regular 
western blotting). Subsequently, the membranes were 
blocked for 1  h and incubated overnight with the pri-
mary antibody at a concentration of 1  µg/ml (Abcam, 
Ref. ab9374) in PBS-Tween20  +  5% non-fat dry milk. 
After rinsing, the membranes were incubated with the 
specific HRP-conjugated secondary antibody in PBS-
Tween20 +  5% non-fat dry milk, which were detected 
by enhanced chemiluminescence (ECL: GE Healthcare) 
following the manufacturers’ instructions. Protein band 
intensity was measured on a GS-800 Calibrated Densi-
tometer (Bio-Rad).
Immunohistochemistry
Tissues were embedded in OCT and cryosections 
(6  µm) were obtained for immunohistochemical analy-
ses. The sections were blocked with 10% BSA in PBS 
with 0.1% Tween 20 and incubated overnight at 4  °C 
with the primary antibody (10  µg/ml: Abcam, ab9374). 
The sections were then incubated with an IgG-HRP-
conjugated secondary antibody (NORDIC Immunol-
ogy) and the chromogenic reaction was developed using 
Table 3 Clinical characteristics of the subjects used in the 
validation phase
F female, M male, AHT arterial hypertension
Subject number Age/gender AHT Diabetes Dyslipidemia
1 Control 62/M Yes No Yes
2 Control 82/M Yes No No
3 Control 86/M Yes No Yes
4 Control 96/M No Yes Yes
5 Control 78/F Yes Yes No
6 Control 81/M Yes No No
7 Control 40/F No No No
8 Control 30/M No No No
9 AS 77/F Yes Yes No
10 AS 86/M Yes No No
11 AS 69/F Yes No No
12 AS 77/M No No No
13 AS 60/F Yes No No
14 AS 75/F Yes No Yes
15 AS 74/M No No Yes
16 AS 74/F Yes Yes No
Mean control 75% M 62.75% 25% 37.75%
Mean AS 37.5% M 75 25% 25%
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3,3′-diaminobenzidine. Sections were counterstained 
with hematoxylin prior to dehydration and coverslip-
ping. As a negative control, the complete immuno-
histochemical procedure was performed on adjacent 
sections without adding the primary antibody. To quan-
tify the DAB stained area, an orthonormal transforma-
tion of the RGB images was applied using an ImageJ 
plugin based on Ruifrok and Johnston’s method for color 
deconvolution.
Selected reaction monitoring
Prior to mass spectrometry (MS) analysis in the LC–MS/
MS system, crude plasma samples were reduced, digested 
and cleaned on Pep-Clean spin columns (Pierce) accord-
ing to the manufacturer’s instructions. LC–MS/MS was 
performed on a TEMPO nano LC system (Applied Bio-
systems) combined with a nano LC Autosampler cou-
pled to a modified triple quadrupole (4000 QTRAP LC/
MS/MS, Applied Biosystems). Theoretical SRM tran-
sitions were designed using MRMpilot software v1.1 
(ABSciex), and the MIDAS acquisition method and Sky-
line were used for the analysis, including the theoretical 
transitions.
Statistical analysis
Statistical analyses were performed using SPSS 15.0 soft-
ware for Windows (SPSS Inc.). A Kolmogorov–Smirnov 
test was applied to evaluate the normal distribution of the 
continuous variables in the population analyzed. When a 
normal distribution was demonstrated, a comparison of 
the means was performed using a t-Student test. For pop-
ulations with no normal distribution, the non-parametric 
Mann–Whitney U test was used. Discrete variables, such 
as sex or the presence/absence of risk factors, were com-
pared using Fisher’s exact test. For all tests, statistical sig-
nificance was accepted when p < 0.05.
Results
To identify proteins of interest in CAS, two complementary 
proteomic approaches were applied to two different types 
of CAS samples (tissue and secretome), the in-gel separa-
tion of proteins 2D-DIGE MALDI-MS/MS and liquid-
chromatography separation of peptides (LC–MS/MS). The 
results obtained were validated in an independent cohort 
of plasma samples to support their translation to a clinical 
setting. In tissue 2D-DIGE analysis, we identified 3 spots in 



























Fig. 2 2D‑DIGE results. a Representative fluorescence DIGE image, showing the differentially expressed spots corresponding to AACT. On the right, 
the spot intensity in 3D of one of the three spots corresponding to AACT is shown. The differences between controls and patients were consistent 
in the 8 gels studied. b Fragmentation spectra of the proteotypic peptides used for AACT identification by MALDI‑MS/MS. The fragments of the y 
ion series are shown in blue, while the b ion series are shown in red
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cases, the MASCOT score of these spots was higher than 
70 and they were about twofold more intense in stenotic 
valves (Table 4).
We also performed a secretome analysis using l-lysine 
2HCl (U-13C6, 97–99%) and 10  mg/ml l-Arginine HCl 
(U-13C6, 97–98%). AACT was one of the secreted pro-
teins that incorporated the labeled amino acids in the AS 
group alone. AACT was analyzed using the SecretomeP 
software [15] and it was predicted to be a secreted pro-
tein. Its signal peptide indicated secretion by the classical 
pathway and in the absence of the signal peptide, it had 
an NN-score >0.5, indicative of non-classical secreted 
proteins. As such, it seems likely that AACT is secreted 
by the classical pathway.
We validated these results in an independent cohort 
of control and CAS subjects by immunohistochem-
istry, in western blots and by SRM. AACT accumu-
lated most strongly in the tissue from the CAS patients 
(Fig.  3), primarily in the endothelium on the aortic side 
and in the fibrosa (controls mean  =  5.41  ±  1.43; CAS 
mean = 14.35 ± 2.951: p = 0.023). As indicated, the pro-
teomic results were also validated in 2-D western blots 
using three different CAS samples: tissue, plasma and 
secretome (Fig.  4). The relative intensity of this protein 
was 1.5 higher in CAS tissue than in the control samples 
and we also found a significant increase in the plasma 
from CAS patients (mean =  18.00 ±  1.75) relative to the 
controls (mean = 4.82 ± 0.63: p = 0.042). Similar results 
Table 4 List of the alpha 1 antichymotrypsin isoforms identified in the 2D-DIGE analysis of AS patients versus controls
The Uniprot accession number is shown, along with the MASCOT score, sequence coverage, number of matched peptides, expect score, variation between the 
patients and the control groups (ratio AS/C), theoretical isoelectric point (pI) and molecular weight (MW), and experimental isoelectric point (pI) and molecular weight 
(MW) in kDa












Theo. pI Theo. 
MW
Exp. pI Exp. MW
Alpha‑1‑antichymo‑
trypsin
P01011 394 23 13 1.6e−034 1.96 5.33 47.62 4.7 95
174 37 16 1.6e−012 1.94 5.33 47.62 4.65 104


















Fig. 3 Validation of the AACT protein using IHC. Stronger expression of AACT is observed in the endothelium on the aortic side and, to a greater 
extent in the fibrosa of the stenotic valves when compared to the controls. DAB staining is brown and is indicated by the arrows. Statistical analyses 
showed significant differences (*p = 0.023). Amplified images at ×100 magnification
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were obtained when analyzing the secretome (controls 
mean = 0.41 ± 0.01; CAS mean = 1.48 ± 0.42: p < 0.001).  
In terms of the validation of the SRM secretome sam-
ples, two different peptides and three transitions of each 
of these were measured  (Fig. 5). The expression of both 
was significantly higher in the CAS patients than in the 
controls, and significant differences between the two 
study groups were also evident in the plasma samples 
(Table 5).
Discussion
Aortic stenosis is a progressive disease with aortic valve 
sclerosis as the first manifestation, which ultimately 
leads to valve dysfunction [4]. Over the last few years, 
great efforts have been made to understand the physio-
logical and pathological mechanisms implicated in CAS. 
Calcification of the native aortic cups in this disease is a 
complex process, which appears to be related to inflam-
mation and ossification [16]. Nevertheless, the mecha-
nisms underlying degenerative heart valve disease still 
remains largely unclear, especially when compared with 
our understanding of the mechanisms underlying other 
cardiovascular diseases like heart failure and atheroscle-
rotic disease. Due to the high social costs associated with 
CAS healthcare, there is a strong unmet clinical need to 
find markers that aid early diagnosis, estimate the long-
term prognosis, monitor treatment response and pre-
dict potential adverse effects in CAS patients. By using 
multi-omics approaches, we hoped to define markers 
that may potentially serve to diagnose the disease ear-
lier than traditional methods, such as echocardiography 
[11]. Novel tools for easier diagnosis will reduce the high 
morbidity and mortality associated to surgery, and they 
may provide a solution for those patients who cannot be 
operated on, as well as improving patient management.
The use of different proteomic techniques on distinct 
samples allowed us to identify AACT as a potential diag-
nostic marker for CAS. This was validated in an inde-
pendent cohort of subjects using orthogonal techniques 
to analyze tissue, the secretome and plasma samples. 
Taking into account these results, AACT detection and 
its quantification could define AS, and as we believe that 
AACT may be a potential diagnostic marker of CAS, 























Fig. 4 Validation of the AACT protein in Western Blots. a Bidimensional immunodetection analysis of tissue samples in which differences in the 
expression of the isoforms is indicated by arrows. b Immunodetection of the secretome samples. The band was more intense in the patient group 
than in the controls. c Immunodetection of the plasma samples. Again, the band in the plasma from the patients was more intense than in the 
controls. Quantification by densitometry is also shown in the figure and the AACT levels are clearly higher in the CAS patients in all cases
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Although the exact role of AACT in CAS is unknown, 
it has been postulated to have several effects on the car-
diovascular system. AACT is a serine protease inhibi-
tor affecting acute phase proteins, and it induces tumor 
necrosis factor (TNF)-α and NF-κB expression [17], 
which both have anti-inflammatory properties. Addi-
tionally, AACT is thought to afford protection during 
ischemia reperfusion by inhibiting neutrophil accumu-
lation into the ischemic-reperfused myocardium and 
by inactivating cytotoxic metabolites released from 
Fig. 5 SRM validation of the differences in AACT found using LC‑MS/MS. a Chromatograms of secretome samples showing the transitions of the 
2 proteotypic peptides: ITLLSALVETR (A.1) and LYGSEAFATDFQDSAAAK (A.2). As it is shown in the figure, the m/z values selected in the first quadru‑
pole were 608.37 and 946.44, respectively. On the right, quantification of the three transitions (area under the curve) that were monitored for each 
peptide. The different m/z values selected in the third quadrupole are indicated in the figure. b Chromatograms of plasma samples showing the 
transitions of the proteotypic peptide AVLDVFEEGTEASAATAVK (m/z 954.48) and quantification of each transition (area under the curve) in plasma 
samples. The different m/z values selected in the third quadrupole are indicated in the figure
Table 5 Statistical analysis of the SRM
The peptide sequence is shown, along with the selected transitions (T) and the statistical significance (p value)
Peptide T Mean ± SEM p value
1 ITLLSALVETR T1 Control: 22,938 ± 11,790; CAS: 418,327 ± 245,046 0.0032
T2 Control: 77,287 ± 41,645; CAS: 1,395,651 ± 811,858 0.0025
T3 Control: 42,469 ± 22,863; CAS: 792,453 ± 460,476 0.0032
2 LYGSEAFATDFQDSAAAK T1 Control: 32,992 ± 10,156; CAS: 77,827 ± 11,396 0.0055
T2 Control: 42,505 ± 14,734; CAS: 97,228 ± 14,444 0.0095
T3 Control: 31,132 ± 8909; CAS: 75,803 ± 10,252 0.0025
3 AVLDVFEEGTEASAATAVK T1 Control: 0.024 ± 0.001; CAS: 0.035 ± 0.006 0.0023
T2 Control: 0.022 ± 0.001; CAS: 0.030 ± 0.006 0.0325
T3 Control: 0.024 ± 0.001; CAS: 0.035 ± 0.006 0.0482
Page 9 of 10Martin‑Rojas et al. Clin Proteom  (2017) 14:12 
neutrophils [18]. This protein is a member of the serpin 
family [19] and it is also known as serpin 3. Although it 
is mainly synthesized in the liver [19–23], we have also 
found it expressed in aortic valves. It is well known that 
the levels of acute-phase proteins in plasma are elevated 
in response to inflammation and rupture [24, 25]. Thus, 
endothelial damage could explain the over expression of 
AACT in CAS, as well as the inflammation, which seems 
to be involved in the development of the disease [26–29].
Protein changes observed in tissue are important 
since they reveal the specific molecular processes tak-
ing place in the damaged organ. Nevertheless, valve tis-
sue is not very accessible to clinicians and hence, it is 
significant that the increase in AACT is also evident in 
the secretome of CAS samples, as well as in the plasma 
of patients. The analysis of the secretome and plasma 
showed that this protein is released directly from the 
stenotic valve in response to the development of CAS, 
such that higher levels of ACCT imply further CAS 
development, which implies vascular surgery.
While, potential biomarkers found in plasma are less 
specific than those found in tissues, we have demon-
strated the valvular origin of the increase in AACT in this 
biological fluid. This sample is easily accessible to clini-
cians, as extraction requires non-invasive methods and 
it is routinely used in clinical analysis. Besides, current 
methods such as echocardiography are time-consuming 
and expensive when compared with plasma analysis. 
Moreover, high qualified staff are needed to interpret 
images due to their complexity and thus it would be easier 
to measure AACT in a clinical setting in order to diagnose 
CAS. It is now important to perform a study with a larger 
number of patients with different grades of injury in order 
to confirm that AACT levels increase with the severity of 
the disease as a physiological response to the processes 
that take place in the stenotic aortic valve. This would 
allow us to establish ranges of protein concentrations in 
an attempt to predict which patients may develop a severe 
form of CAS, making it possible to apply more personal-
ized treatment. In addition a prospective study would 
allow us to confirm the prognostic value of this protein.
Conclusions
Alpha-1-antichymotrypsin seems to be an important 
indicator for clinicians regarding the progression of CAS. 
These data are important considering the aging of the 
population where cardiovascular diseases, in this case 
CAS, are becoming an increasing economic and social 
burden in Western countries. Future studies with plasma 
samples taken at different time points and taken from 
patients with distinct disease progression will be neces-
sary to analyze the potential role of AACT as a prognos-
tic and diagnostic marker of CAS in more depth.
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